ANUHPHR

Anuh Pharma Share Price

 

 

Start SIP in ANUHPHR

Start SIP

Performance

  • Low
  • ₹75
  • High
  • ₹77
  • 52 Week Low
  • ₹69
  • 52 Week High
  • ₹115
  • Open Price₹76
  • Previous Close₹76
  • Volume49,174
  • 50 DMA₹78.43
  • 100 DMA₹80.68
  • 200 DMA₹84.87

Investment Returns

  • Over 1 Month + 3.04%
  • Over 3 Month -6.55%
  • Over 6 Month -17.92%
  • Over 1 Year -6.88%

Smart Investing Starts Here Start SIP with Anuh Pharma for Steady Growth!

Invest Now

Anuh Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 18
  • PEG Ratio
  • -1.1
  • Market Cap Cr
  • 752
  • P/B Ratio
  • 2.3
  • Average True Range
  • 3.36
  • EPS
  • 4.17
  • Dividend Yield
  • 2
  • MACD Signal
  • 0.85
  • RSI
  • 42.36
  • MFI
  • 49.55

Anuh Pharma Financials

Anuh Pharma Technicals

EMA & SMA

Current Price
₹74.99
-0.87 (-1.15%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹78.36
  • 50 Day
  • ₹78.43
  • 100 Day
  • ₹80.68
  • 200 Day
  • ₹84.87

Resistance and Support

75.57 Pivot Speed
  • R3 78.13
  • R2 77.47
  • R1 76.23
  • S1 74.33
  • S2 73.67
  • S3 72.43

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Anuh Pharma has an operating revenue of Rs. 767.68 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 9% is okay, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 62 which is a FAIR score but needs to improve its earnings, a RS Rating of 43 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Anuh Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-06 Quarterly Results
2025-11-07 Quarterly Results
2025-08-08 Quarterly Results & Others To consider other business matters. per share(30%)Final Dividend
2025-05-23 Audited Results, Dividend & Bonus issue
2025-02-07 Quarterly Results & Others To consider other business matters. per share(30%)Final Dividend
Date Purpose Remarks
2025-08-15 FINAL Rs.1.50 per share(30%)Final Dividend (RD date revised)
View Anuh Pharma Dividend History Arrow
Date Purpose Remarks
2025-07-15 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 5/-

Anuh Pharma F&O

Anuh Pharma Shareholding Pattern

71.82%
0%
0%
0%
23.74%
4.44%

About Anuh Pharma

  • NSE Symbol
  • ANUHPHR
  • BSE Symbol
  • 506260
  • Joint Managing Director
  • Mr. Ritesh B Shah
  • ISIN
  • INE489G01022

Similar Stocks to Anuh Pharma

Anuh Pharma FAQs

Anuh Pharma share price is ₹74 As on 21 February, 2026 | 18:40

The Market Cap of Anuh Pharma is ₹751.6 Cr As on 21 February, 2026 | 18:40

The P/E ratio of Anuh Pharma is 18 As on 21 February, 2026 | 18:40

The PB ratio of Anuh Pharma is 2.3 As on 21 February, 2026 | 18:40

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23